Top 20 BioPharma Companies based on 2018 Total Revenue

Top 20 BioPharma Companies based on 2018 Total Revenue

The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices, which were emerged as one of major revenue generator in 2018, with the development of new products and devices. The year 2018 also proved to be a record with approval of 55 novel drugs. The top 20 companies on the ledger changed from their 2017 ranking, leading to major ups & downs in the positions. Johnson and Johnson again proved to be the among the highest rank in 2018 generating revenue of $81.5B. Our team at PharmaShots has compiled a list of top 20 pharma companies based on their 2018 total revenue.

Total Revenue: $13.45B                                                               Total Employees: ~7,800     

Pharma Segment Revenue: $10.86B                                     Non-Pharma Segment Revenue: $2.56B

Founded Year:  1978                                                                      Headquarter: Massachusetts, United States

Market Cap: ~$46B                                                                         Stock Exchange: NASDAQ

Biogen is a global biopharmaceutical company focusing on neurology with a broad portfolio including Tecfidera, Avonex, Plegridy, Tysabri and Fampyra. Biogen has expanded its business in 2018, with the acquisition of BIIB100 & BIIB110 candidates from Karyopharm and AliveGen respectively and further collaborated with Pfizer for BIIB100. The company has expanded its partnership with Ionis Pharmaceuticals with ten year agreement for the development of antisense oligonucleotide (ASO) drug candidates in neurological diseases. Biogen has also entered into a research collaboration with C4 Therapeutics (C4T) for its novel protein degradation platform.

Total Revenue: $15.42B                                                                 Total Employees: ~16,962

Pharma Segment Revenue: $15.26B                                       Non-Pharma Segment Revenue: $0.01B

Founded Year: 1986                                                                         Headquarter: New Jersey, United States

Market Cap: ~$66B                                                                          Stock Exchange: NASDAQ

Celgene is an integrated global biopharmaceutical company focused on developing therapies for cancer & inflammatory diseases. Celgene’s numerous key products are in P-III trials including Revlimid, Otezla, evaluated in patients with r/r follicular or marginal zone lymphoma & Behcet’s disease respectively. In 2019, Celgene has been acquired by BMS for $74B.

Total Revenue: $15.78B                                                                  Total Employees: ~17,000

Pharma Segment Revenue: $15.42B                                         Non-Pharma Segment Revenue: $0.36B

Founded Year: 1950                                                                          Headquarter: Dublin, Ireland

Market Cap: ~$48B                                                                            Stock Exchange: NYSE

Allergan is an Irish pharmaceutical company focused on developing & commercializing pharmaceuticals, devices, biologic, surgical and regenerative medicine for the people around the globe. Allergan didn’t has much difference in revenue in comparison to its 2017 revenue. Allergan’s blockbuster products, Botox cosmetic, Botox therapeutic, Vraylar, and Juvederm added nearly $1B to its 2018 revenue.

Total Revenue: $16.90B                                                               Total Employees: ~43,202

Pharma Segment Revenue: $16.67B                                     Non-Pharma Segment Revenue: $0.23B

Founded Year: 1989                                                                       Headquarter: Bagsværd, Denmark

Market Cap: ~$97B                                                                         Stock Exchange: Copenhagen

Novo Nordisk is a global healthcare company focusing on therapies for Diabetes, Obesity, Hemophilia and growth disorders. 2018 was a progressive year for Novo Nordisk as it reached its target with the launch of Ozempic for the treatment of Type-2 Diabetes. Novo Nordisk is expected to increase its sales by 2-5% in 2019.

Total Revenue: $18.854B                                                             Total Employees: ~45,000

Pharma Segment Revenue: $17.48B                                     Non-Pharma Segment Revenue: $1.36B

Founded Year: 1944                                                                       Headquarter: Petah Tikva, Israel

Market Cap: ~$16B                                                                         Stock Exchange: NYSE 

Teva Pharmaceutical is an Israeli multinational pharmaceutical company focused on generics, specialty medicines and biopharmaceuticals. Company’s specialty portfolio includes Capaxone for multiple sclerosis, Ajovy for the treatment of migraine & Austedo for movement disorder. Teva’s biosimilars (developed by Celltrion) were approved by the FDA in 2018, including Truxima & Herzuma biosimilar to rituximab & trastuzumab respectively.

Total Revenue: $22.09B                                                                Total Employees: ~50,000

Pharma Segment Revenue: $21.04B                                      Non-Pharma Segment Revenue: $1.04B

Founded Year:  1999                                                                       Headquarter: Cambridge, United Kingdom

Market Cap: ~$105.8B                                                                    Stock Exchange: LSE

AstraZeneca is a global, biopharmaceutical company focusing on Oncology, Respiratory, Neurology, Autoimmune and other therapy areas. In Dec’18 AstraZeneca and Merck’s Lynparza (olaparib) received FDA’s approval as 1L treatment for BRCA-Mutated Advanced Ovarian Cancer and signed an immune-oncology clinical collaboration with AVEO oncology. In May’18 AstraZeneca has also received FDA’s approval for its Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalemia in adults.

Total Revenue: $22.12B                                                                 Total Employees: ~11,000

Pharma Segment Revenue: $21.67B                                      Non-Pharma Segment Revenue: $0.45B

Founded Year: 1987                                                                        Headquarter: California, United States

Market Cap: ~$84B                                                                          Stock Exchange: NASDAQ

Gilead Sciences is a research-based biopharmaceutical company with a broad portfolio of drugs. Biktarvy, Descovy, Odefsey, Genvoya, Stribild are approved in the US & EU for HIV infection in adults. Biktarvy received FDA’s approval in Feb’18 for the treatment-naive HIV-1 infected in adults.

Total Revenue: $22.56B                                                                  Total Employees: ~23,300

Pharma Segment Revenue: $22.56B                                        Non-Pharma Segment Revenue: Nil

Founded Year: 1989                                                                          Headquarter: New York, United States

Market Cap: ~$75B                                                                            Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on Oncology, Cardiovascular, Immunology and Fibrosis. Its blockbuster drugs, Opdivo (nivolumab) for cancer & Eliquis as anticoagulant positioned BMS in the top 20 global pharma companies. BMS remained to be in the highlights, with its acquisition of Celgene in early 2019. The acquisition will boost up BMS’ pipeline in Oncology, Immunology, Inflammation & Cardiology.

Total Revenue: $23.74B                                                               Total Employees: ~21,000

Pharma Segment Revenue: $22.53B                                     Non-Pharma Segment Revenue: $1.2B

Founded Year: 1980                                                                      Headquarter: California, United States

Market Cap: ~$120B                                                                     Stock Exchange: NASDAQ

Amgen is one of the leading biotechnology company developing novel therapies focused on Cardiology, Oncology, Neurology, Nephrology, and Inflammatory diseases. The company’s total revenue increased by 7%, leading to a total increment of $6.2B. The company recently launched products Repatha (evolocumab), Prolia (denosumab), Kyprolis (carfilzomib) and Xgeva (denosumab) which presented a double- digit growth.

Total Revenue: $24.55B                                                                 Total Employees:  ~38,000

Pharma Segment Revenue: $22.93B                                      Non-Pharma Segment Revenue: $1.62B

Founded Year: 1901                                                                        Headquarter: Indiana, United States 

Market Cap: ~$139B                                                                       Stock Exchange: NYSE

Eli Lilly and Company is a global pharmaceutical firm focused on developing therapies in the areas of diabetes, lung cancer, osteoporosis & men’s health. In Sep’18, Lilly’s animal health business Elanco completed its IPO on NYSE. In 2018, it had collaborated with Hydra Biosciences, AC immune to develop immune & neurodegenerativetherapies respectively. The FDA granted fast track designation to Lilly’s Olumiant for SLE in Dec’18.

Total Revenue: $30.57B                                                                Total Employees: ~103,000

Pharma Segment Revenue: $9.43B                                         Non-Pharma Segment Revenue: $21.14B

Founded Year: 1900                                                                        Headquarter: Illinois, United States

Market Cap: ~$130B                                                                       Stock Exchange: NYSE

Abbott Laboratories is an American healthcare company with a broad pipeline of generics, diagnostic, natural products, Cardiovascular and Neuromodulation products. In 2018, Abbott received FDA’s approval for the Advisor HD grid mapping catheter, sensor enabled MitraClip, a heart valve repair device, HeartMate 3 left ventricular assist device (LVAD), XIENCE Sierra drug eluting stent system

Total Revenue: $32.73B                                                                 Total Employees: ~30,000   

Pharma Segment Revenue: $32.73B                                       Non-Pharma Segment Revenue: Nil

Founded Year: 1900                                                                        Headquarter: Illinois, United States 

Market Cap: ~$122B                                                                       Stock Exchange: NYSE 

AbbVie is a global, research-based biopharmaceutical company that develops therapies majorly for Chronic autoimmune diseases, Oncology, Virology with additional targets like cystic fibrosis and Women’s health. In Oct’18 Health Canada approved AbbVie’s Orilissa (elagolix) for pain associated with endometriosis. Its blockbuster product Humira (adalimumab) is a biologic therapy and is approved in multiple countries globally. In Dec’18, AbbVie pact a deal with Lupin to develop novel therapies for cancer.

Total Revenue: $38.85B                                                                Total Employees: ~100,000

Pharma Revenue: $38.85B                                                          Non-Pharma Segment Revenue: Nil   

Founded Year: 1973                                                                        Headquarter: Paris, France

Market Cap: ~$108.4B                                                                   Stock Exchange: Euronext

Sanofi is a global healthcare leader providing healthcare solutions in 170+ countries around the world. In 2018, Sanofi had 81 projects in development, including molecular entities and 35 projects either in P-III or some submitted for approval. Sanofi also had major key events in 2018, including an acquisition of Bioverativ for $11.6B, approval of Libtayo for mCSCC in the US, and change of Sanofi’s stock market listing from NYSE to NASDAQ.

Total Revenue: $40.99B                                                            Total Employees: ~100,000                

Pharma Segment Revenue: $30.80B                                   Non-Pharma Segment Revenue: $10.18B

Founded Year: 2000                                                                      Headquarter: Brentford, United Kingdom

Market Cap: ~$206B                                                                    Stock Exchange: LSE

GlaxoSmithKline is a global healthcare company serving the world with drugs, vaccines & consumer healthcare products and is a leader in the areas of respiratory and HIV. GSK has a broad portfolio including the key products Trelegy for Asthma/COPD, Nucala for Severe Asthma and Triumeq/Tivicay for HIV. In Dec’18, GSK signed an agreement with Pfizer for the consumer healthcare joint venture. In Jul’18 FDA’s approval of Krintafel (tafenoquine) also strengthened GSK’s portfolio.

Total Revenue: $42.29B                                                                 Total Employees: ~69,000

Pharma Segment Revenue: $42.29B                                       Non-Pharma Segment Revenue: Nil

Founded Year: 1891                                                                        Headquarter: New Jersey, United States

Market Cap: ~$209B                                                                       Stock Exchange: NYSE

Merck & Co. is a global health care company delivering innovative health care products with its prescription medicines, vaccines, biologic therapies and animal health care products. In Sep’18 Merck’s Pifeltro (doravirine) received the US FDA approval for HIV-1 infection. Merck has numerous successful therapies in its portfolio, including Keytruda, Januvia, Gardasil, which had net sales of $7.10B, $5.91B, $3.15B in 2018 respectively. The animal health division of Merck generated sales of $4.212B in 2018.

Total Revenue: $44.67B                                                                Total Employees: ~ 116,998

Pharma Segment Revenue: $14.93B                                      Non-Pharma Segment Revenue: $29.75B

Founded Year: 1863                                                                        Headquarter: Leverkusen, Germany 

Market Cap: ~$61B                                                                          Stock Exchange: ETR

Bayer is a leading life science firm with three divisions- pharmaceuticals, consumer health and crop science. In 2018, Bayer revenue increased by 4.5%, leading it to a total of $44.5B. Leo Pharma has acquired 
Bayer’s dermatology unit along with its 450 employees in 2018. Bayer’s BAY94-9027 received EMA’s CHMP marketing authorization for the treatment of hemophilia A for patients aged ≥12yrs.

Total Revenue: $51.9B                                                                   Total Employees: ~125,161 Employees    

Pharma Segment Revenue: $42.3B                                         Non-Pharma Segment Revenue: $9.6B

Founded Year: 1996                                                                        Headquarter: Basel, Switzerland

Market Cap: ~$213B                                                                       Stock Exchange: SIX Swiss Exchange, NYSE

Novartis is a multinational group of company specializing in the research, development, manufacturing and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. In 2018, Novartis entered into a collaboration with Pfizer for NASH and signed an exclusive in-licensing agreement with Galapagos NV and MorphoSys AG for MOR106 (Biologic). Novartis has also spin-off Alcon, a division specialized in eye care. Novartis also appointed Vasant Narasimhan as its new CEO in 2018.

Total Revenue: $53.64B                                                                Total Employees: ~92,400

Pharma Segment Revenue: $53.64B                                      Non-Pharma Segment Revenue: Nil

Founded Year: 1849                                                                        Headquarter: New York, United States

Market Cap: $239.5B                                                                     Stock Exchange: NYSE 

Pfizer is a research-based, global biopharmaceutical company with a vast portfolio, including vaccines and health care products. In 2018, Pfizer also received several FDA approvals, including Vizimpro (dacomitinib) for NSCLC, Talzenna (talazoparib) for Breast Cancer, Lorbrena (lorlatinib) for ALK+ NSCLC. 2018 proved to be a successful year for Pfizer’s biosimilar portfolio with emerging approvals of Retacrit (epoetin alfa–epbx, biosimilar) & Nivestym (filgrastim–aafi, biosmilar) for Anemia & Neutropenia respectively. In Oct’18 Pfizer also appointed Dr. Albert Bourla as its new CEO and collaborated with GSK for building a healthcare Joint Venture.

Total Revenue: $56.91B                                                                Total Employees: ~92,400

Pharma Segment Revenue: $44.10B                                      Non-Pharma Segment Revenue: $12.81B

Founded Year: 1896                                                                         Headquarter: Basel, Switzerland

Market Cap: $237B                                                                     Stock Exchange: SIX Swiss Exchange 

Roche is a Swiss multinational healthcare company operating worldwide under pharmaceuticals and diagnostics divisions. In 2018, Roche achieved a positive growth in both the divisions and delivered therapies like Xofluza (baloxavir marboxil) for influenza and targeted serious diseases like cancer, multiple sclerosis, & hemophilia. Roche is also making progress in driving digitization to support product development and advancing personalized healthcare. In Jun’18 Roche launched Ocrevus (ocrelizumab) to treat both primary progressive multiple sclerosis (PPMS) and relapsing MS (RMS) which proved to be a big hit in a Roche’s history.

Total Revenue: $81.58B                                                                Total Employees: ~135,100

Pharma Segment Revenue: $40.73B                                       Non-Pharma Segment Revenue: $40.85B

Founded Year: 1887                                                                        Headquarter: New Jersey, United States

Market Cap: ~$361B                                                                       Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational medical device, pharmaceutical, and consumer packaged goods manufacturing company. The consumer department of the company focuses on Baby & Beauty, Health & Healing Products and the medical device sector is focused on Orthopedics, and Cardiovascular Diseases. On Feb’18 J&J’s subsidiary Janssen received FDA’s approval for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).

Source: Public Company Annual Reports/10K, Company Website, Market cap source: Google finance| 

Note: Takeda is not included in top 20 list, as its actual revenue is not available (2018 forecasted revenue is $16.03B)

Subscribe To Our News Alert

Join our mailing list to receive the latest news and updates from PharmaShots.

You have Successfully Subscribed!